Table 3.
Results of meta-analyses
| Dyad | Pooled mean cost (I$) | 95%CI |
|---|---|---|
| Hypertension + Musculoskeletal disorder | 13,270 | (12,960–13,580) |
| Hypertension + Diabetes | 14,300 | (13,940–14,660) |
| Hypertension + Respiratory condition | 17,180 | (16,530–17,830) |
| Hypertension + Kidney disease | 17,740 | (17,060–18,420) |
| Hypertension + Heart/vascular condition | 17,880 | (17,520–18,250) |
| Diabetes + Mental health condition | 20,750 | (19,830–21,660) |
| Diabetes + Kidney disease | 32,410 | (32,370–32,440) |
| Respiratory + Heart/vascular condition | 35,070 | (34,890–35,260) |
| Respiratory + Mental health condition | 36,840 | (36,440–37,250) |
| Diabetes + Heart/vascular condition | 37,090 | (35,870–38,310) |
| Cancer + Mental health condition (first year after cancer diagnosis) | 85,820 | (81,930–89,690) |
Legend: Mean cost data were meta-analyzed using a fixed-effects model assuming a normal likelihood for study-specific mean costs. All meta-analyses resulted in I2 values above 95%. Costs are presented in 2021 International Dollars